Studies have suggested that targeting inhibitory PTPN family proteins, including PTPN22, may also serve to boost anti-cancer immune responses and may be used in conjunction with established immune checkpoint blockade and ACT approaches.5 This evidence concerns the gene PTPN22 and cancer.